http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014108725-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-642 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate | 2012-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014108725-A |
| titleOfInvention | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER CONTAINING INTERFERON-ALPHA conjugate |
| abstract | 1. Pharmaceutical composition for the prevention or treatment of cancer, containing interferon-alpha. A composition according to claim 1, wherein interferon-alpha is a substance that binds to an in vivo receptor, exhibiting biological activity identical to or corresponding to the biological activity of native interferon-alpha, and native interferon-alpha, its derivatives, variants or fragments. A composition according to claim 1, wherein interferon-alpha is in the form of a conjugate with a polymer, in which interferon-alpha is conjugated to a polymer. The composition of claim 3, wherein the polymer is selected from the group consisting of polyethylene glycol, an antibody, an antibody fragment, an immunoglobulin, fibronectin, albumin, and elastin constant region. The composition of claim 3, wherein the conjugate to the polymer is prepared by linking interferon-alpha and the immunoglobulin constant region via a non-peptidyl polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylene polyvinyl vinyl polyvinyl alcohol ether, polylactic acid, polylactic-glycolic acid, lipopolymers, chitins, hyaluronic acid, and a combination thereof. 6. A composition according to claim 1, further comprising an anticancer agent selected from the group consisting of a Ras inhibitor, a Raf inhibitor, a MAP / Erk kinase inhibitor (MEK) and a mitogen-activated protein kinase inhibitor (MAPK). The composition of claim 1, further comprising gemcitabine or sorafenib. The composition of claim 6 or 7 for use in the treatment of cancer with k-ras mutation. The composition of claim 6 or 7 for use in the treatment of pancreatic cancer |
| priorityDate | 2011-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.